These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15613909)

  • 1. Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab.
    Zell JA; Yoon EJ; Ignatius Ou SH; Hoefs JC; Chang JC
    Anticancer Drugs; 2005 Jan; 16(1):83-5. PubMed ID: 15613909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
    Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
    J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
    Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
    Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma.
    Visani G; Guiducci B; D'Adamo F; Mele A; Nicolini G; Leopardi G; Sparaventi G; Barulli S; Malerba L; Isidori A; Malagola M; Piccaluga PP
    Leuk Lymphoma; 2005 Mar; 46(3):477-9. PubMed ID: 15621843
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatal reactivation of hepatitis B after chemotherapy for lymphoma.
    Dillon R; Hirschfield GM; Allison ME; Rege KP
    BMJ; 2008 Jul; 337():a423. PubMed ID: 18595895
    [No Abstract]   [Full Text] [Related]  

  • 7. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine.
    Simpson ND; Simpson PW; Ahmed AM; Nguyen MH; Garcia G; Keeffe EB; Ahmed A
    J Clin Gastroenterol; 2003 Jul; 37(1):68-71. PubMed ID: 12811213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined lamivudine and interferon-alpha therapy for chemotherapy-induced reactivation of hepatitis B virus.
    Ohmoto K; Tsuduki M; Yamamoto S
    Am J Gastroenterol; 2003 May; 98(5):1215-6; author reply 1217. PubMed ID: 12809863
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.
    Tsutsumi Y; Kawamura T; Saitoh S; Yamada M; Obara S; Miura T; Kanamori H; Tanaka J; Asaka M; Imamura M; Masauzi N
    Leuk Lymphoma; 2004 Mar; 45(3):627-9. PubMed ID: 15160930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma.
    Cheng AL
    Blood; 1996 Feb; 87(3):1202. PubMed ID: 8562950
    [No Abstract]   [Full Text] [Related]  

  • 11. [A case of drug-induced liver injury caused by entecavir for treatment of hepatitis B virus reactivation during RCHOP in a patient with non-Hodgkin lymphoma].
    Kondo M; Kitada N; Kobayashi M; Morita S; Yoshioka M; Tsuji T; Mori A; Okamoto T; Watari M
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1199-201. PubMed ID: 19620818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.
    Lim KH; Yoon HI; Kang YA; Lee KW; Kim JH; Bang SM; Lee JH; Lee CT; Lee JS
    Korean J Intern Med; 2010 Mar; 25(1):86-92. PubMed ID: 20195409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Icteric hepatitis in a patient with non-Hodgkin's lymphoma treated by rituximab-based chemotherapy].
    Coppola N; Masiello A; Tonziello G; Macera M; Iodice V; Caprio N; Pasquale G
    Infez Med; 2010 Jun; 18(2):127-31. PubMed ID: 20610938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma.
    Li X; Lin Q; Dong M; Wen JY; Wei L; Ma XK; Chen ZH; Wu XY
    Leuk Lymphoma; 2010 Sep; 51(9):1678-85. PubMed ID: 20807095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations.
    Law JK; Ho JK; Hoskins PJ; Erb SR; Steinbrecher UP; Yoshida EM
    Leuk Lymphoma; 2005 Jul; 46(7):1085-9. PubMed ID: 16019563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy.
    Pei SN; Ma MC; Wang MC; Kuo CY; Rau KM; Su CY; Chen CH
    Ann Hematol; 2012 Jul; 91(7):1007-12. PubMed ID: 22273839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of hepatitis B virus reactivation in patients who are hepatitis B surface antigen negative/antibody to hepatitis B core antigen positive and the role of routine antiviral prophylaxis.
    Koo YX; Tan DS; Tan BH; Quek R; Tao M; Lim ST
    J Clin Oncol; 2009 May; 27(15):2570-1; author reply 2571-2. PubMed ID: 19364951
    [No Abstract]   [Full Text] [Related]  

  • 18. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma.
    Kilickap S; Yavuz B; Aksoy S; Sahiner L; Dincer M; Harputluoglu H; Erman M; Aytemir K; Tokgozoglu L; Barista I
    Med Oncol; 2008; 25(4):437-42. PubMed ID: 18415035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab.
    Stange MA; Tutarel O; Pischke S; Schneider A; Strassburg CP; Becker T; Barg-Hock H; Bastürk M; Wursthorn K; Cornberg M; Ott M; Greten TF; Manns MP; Wedemeyer H
    Z Gastroenterol; 2010 Feb; 48(2):258-63. PubMed ID: 20127601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma.
    Faggioli P; De Paschale M; Tocci A; Luoni M; Fava S; De Paoli A; Tosi A; Cassi E
    Haematologica; 1997; 82(1):38-42. PubMed ID: 9107080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.